Connor, Clark & Lunn Investment Management (CC&L)’s Viridian Therapeutics VRDN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-9,130	Closed	-$208K	–	1663
2024 Q3	$208K	Buy	+9,130	New	+$149K	﹤0.01%	1318
2023 Q4	–	Sell	-80,002	Closed	-$1.23M	–	1577
2023 Q3	$1.23M	Sell	80,002 -67,587	-46%	-$1.29M	0.01%	756
2023 Q2	$3.51M	Buy	147,589 +11,324	+8%	+$290K	0.02%	461
2023 Q1	$3.47M	Buy	136,265 +4,726	+4%	+$152K	0.02%	441
2022 Q4	$3.84M	Buy	+131,539	New	+$3.03M	0.02%	406

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s VRDN Position: Q4 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Viridian Therapeutics (VRDN) in Q4 2024, closing a stake of 9,130 shares — an estimated $208K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in VRDN in Q4 2022 and held it in 5 quarters. The position peaked at $3.84M in Q4 2022. 178 funds tracked by Wall St. Rank hold VRDN as of Q4 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Viridian Therapeutics position as of Q4 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 9,130 Viridian Therapeutics shares in Q4 2024, an estimated $208K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Viridian Therapeutics in Q4 2022 and held it in 5 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Viridian Therapeutics position peaked at $3.84M in Q4 2022.
178 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2024, filed 10 Feb 2025.